Conventional Androgen Deprivation Therapy (ADT) With or Without Abiraterone Acetate + Prednisone and Apalutamide Following a Detectable PSA After Radiation and ADT

Summary

This research study is being offered to those patients who have received radiation therapy and who are receiving long-term hormonal therapy for their prostate cancer and whose PSA remains detectable despite having received at least 6, but no more than 12 months of hormonal therapy. The name of the study drugs involved in this study is: * LHRHA (luteinizing hormone-releasing hormone agonist or antagonist) * Abiraterone Acetate * Apalutamide * Prednisone

Timeline

Start

2020-04-20

Primary completion

2024-02-13

Completion

2024-02-13

Drugs

Indications